Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 4Vascular Neoplasms 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Histiocytoma, Angiomatoid Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Granuloma, Plasma Cell 1Granular Cell Tumor 1Glomus Tumor 1Glioma 1Glioblastoma 1Fibrosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 13Temozolomide 11Specimen Handling 8X-Rays 7Biopsy 7Nuclear Medicine Department, Hospital 6Radiation 5Phantoms, Imaging 5erdafitinib 4ulixertinib 3trametinib 3larotrectinib 3dabrafenib 3Radiotherapy 3tipifarnib 2selpercatinib 2palbociclib 2olaparib 2ivosidenib 2ensartinib 2binimetinib 2D2C7-(scdsFv)-PE38KDEL 2vorasidenib 1veliparib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tazemetostat 1selinexor 1sapanisertib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × selinexor × 30 days × Clear all
NCT05099003 2026-05-29

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

National Cancer Institute (NCI)

Phase 1/2 Recruiting
132 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡